A prospective study of magnetic resonance imaging and ultrasonography (MRI/US)-fusion targeted biopsy and concurrent systematic transperineal biopsy with the average of 18-cores to detect clinically significant prostate cancer

BMC Urology

Research Article

Munehiro Yokoyama¹  Mai Oda²  Nobuo Kawauchi²  Yukio Homma³  Jimpei Kumagai³  Hisashi Matsushima⁴  Yoko Hirai⁴  Tomoko Masuda⁴  Yuji Hakozaki⁴  Taro Murata⁴ 

[1] Department of Pathology, Tokyo Metropolitan Police Hospital, Tokyo, Japan;Department of Radiology, Tokyo Metropolitan Police Hospital, Tokyo, Japan;Department of Urology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan;Department of Urology, Tokyo Metropolitan Police Hospital, #4-22-1 Nakano, Nakano-ku, 164-0001, Tokyo, Japan;

关键词: Clinically significant prostate cancer;    Targeted biopsy;    MRI/US fusion biopsy;    PI-RADS version 2 score;    Extended biopsy;   

DOI  :  10.1186/s12894-017-0310-7

 received in 2017-01-30, accepted in 2017-12-05,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThis study compared the detection rates for clinically significant prostate cancer (CSPC) between magnetic resonance imaging and ultrasonography (MRI/US)-fusion-targeted biopsy (TB), systematic biopsy (SB) and combination of TB and SB.MethodsThis prospective study evaluated simultaneous TB and SB for consecutive patients with suspicious lesions that were detected using pre-biopsy multiparametric MRI. A commercially available real-time virtual sonography system was used to perform the MRI/US-fusion TB with the transperineal technique. The prostate imaging reporting and data system version 2 (PI-RADS v2) was assigned to categorize the suspicious lesions.ResultsA total of 177 patients were included in this study. The detection rate for CSPC was higher using SB, compared to TB (57.1% vs 48.0%, p = 0.0886). The detection rate for CSPC was higher using the combination of TB and SB, compared to only SB (63.3% vs 57.1%, p = 0.2324). Multivariate analysis revealed that PIRADS v2 category 4 and an age of <65 years were independent predictors for TB upgrading (vs. the SB result).ConclusionsPI-RADS v2 category 4 and an age of <65 years were predictive factors of upgrading the Gleason score by MRI/US-fusion TB. Thus, MRI/US-fusion TB may be appropriate for patients with those characteristics.Trial registrationThis study was retrospectively registered at the University Hospital Medical Information Network (UMINID000025911) in Jan 30, 2017.

【 授权许可】

CC BY   
© The Author(s). 2017